Get the Stockscreener App
2.39
1.24%
-0.03
Biocardia Inc stock is traded at $2.39, with a volume of 173.20K.
It is down -1.24% in the last 24 hours and up +6.22% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$2.42
Open:
$2.3578
24h Volume:
173.20K
Relative Volume:
1.44
Market Cap:
$11.65M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.339
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
+12.74%
1M Performance:
+6.22%
6M Performance:
+12.40%
1Y Performance:
-23.52%
1-Day Range:
$2.3109
$2.405
1-Week Range:
$2.07
$2.45
52-Week Range:
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.5846 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.171 | 316.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
3.14 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.24 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia files prospectus for resale of 549K shares; stock down 8.6% - MSN
BioCardia Registers 549,392 Shares for Potential Resale by Investors - MarketScreener
BioCardia (BCDA) Proposes Offering of 549K Common Shares | BCDA Stock News - GuruFocus
BCDA boosts ATM capacity to $3.63M; float rules cap issuance | BCDAW SEC FilingForm 424B5 - Stock Titan
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial - Newsfile
Insider Buying: David Mcclung Acquires Shares of BioCardia Inc (BCDA) - GuruFocus
BioCardia Completes Private Placement Agreement - TipRanks
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System - Yahoo Finance
BCDABioCardia Reports First Quarter 2025 Business Highlights and Financial Results - Revista ADVFN
Biocardia CEO Peter Altman acquires $221 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $221 in company stock - Investing.com
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - The Manila Times
BioCardia Reveals Latest Progress on Revolutionary Cell Therapy for Heart Failure at Major Healthcare Conference - Stock Titan
BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey
BioCardia’s Earnings Call: Progress Amid Financial Strain - TipRanks
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo Finance
Biocardia 2024 Q2 Earnings Misses Targets as Revenue Declines 93% - AInvest
BioCardia Reports Positive Q1 2025 Progress - TipRanks
Earnings call transcript: BioCardia’s Q1 2025 results show clinical progress - Investing.com
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan
BioCardia’s Hidden Catalysts: Why Cardiac Regenerative Medicine’s Next Breakthrough Is Undervalued - AInvest
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - The Manila Times
BioCardia to Host Q1 2025 Corporate Update and Financial Results - GuruFocus
Insider Buying Surges in May. Especially These 5 Stocks - 24/7 Wall St.
BioCardia (BCDA) Expands Enrollment for Phase 3 CardiAMP HF II T - GuruFocus
BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Nigeria
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jun 30 '25 |
Buy |
2.08 |
24,096 |
49,999 |
165,862 |
| STERTZER SIMON H | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
192,654 |
| Blank Andrew Scott | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
346,023 |
| Altman Peter | President and CEO |
May 30 '25 |
Buy |
2.21 |
100 |
221 |
141,766 |
| Altman Peter | President and CEO |
May 20 '25 |
Buy |
2.08 |
1,600 |
3,328 |
140,966 |
| Altman Peter | President and CEO |
May 22 '25 |
Buy |
1.89 |
700 |
1,323 |
141,666 |
| Altman Peter | President and CEO |
May 16 '25 |
Buy |
2.43 |
300 |
730 |
139,366 |
| Altman Peter | President and CEO |
May 14 '25 |
Buy |
2.99 |
100 |
299 |
139,066 |
| KRASNO RICHARD M | Director |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
16,268 |
| McClung David | Chief Financial Officer |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
43,131 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):